Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations

NCT ID: NCT06264531

Last Updated: 2026-01-22

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-01-16
• Study Completion Date: 2029-01-15

Brief Summary

Brain arteriovenous malformations (AVMs) are responsible for hemorrhagic strokes, particularly in children and young adults. They can also be responsible for chronic neurological disorders: motor or sensory deficits, disturbances of higher functions, epilepsy or disabling headaches. The management of brain AVMs is complex and requires a multidisciplinary approach in an expert center. Available therapies include endovascular embolization, neurosurgical resection and/or radiosurgery. These procedures carry a risk of neurological complications, and are reserved for small AVMs located at a distance from highly functional cerebral structures. To date, no drug therapy is recommended if interventional treatment is not possible.

Several studies on resected brain AVM tissue have demonstrated that these malformations are the site of significant evolutionary inflammatory and neo-angiogenesis processes. Other studies have specifically shown that VEGF (vascular endothelial growth factor) levels are increased in AVMs. More recently, a pre-clinical study showed that anti-angiogenic treatment with Bevacizumab reduced vascular proliferation within AVMs in mice. Finally, a Phase II clinical trial in patients with Rendu-Osler disease (a genetic vascular disorder characterized by recurrent epistaxis, cutaneous telangiectasia and the presence of visceral AVMs) showed a clinical benefit of IV Bevacizumab on the symptomatology of these vascular malformations, with a reduction in the risk of hemorrhage and the extent of hepatic arteriovenous shunts. A randomized Phase III trial is currently underway (NCT03227263) to assess the efficacy of IV Bevacizumab in Rendu-Osler disease.

The aim of our study is to assess the efficacy of IV Bevacizumab on the disabling symptoms associated with symptomatic brain AVMs.

Conditions

Cerebral AV Malformation

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

bevacizumab

Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections

Group Type: EXPERIMENTAL

Bevacizumab

Intervention Type: DRUG

Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections

placebo

NaCl 0.9% as a slow infusion over 90 minutes every 14 days for a total of 6 injections

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections

Interventions

Bevacizumab

Bevacizumab 5 mg/kg as a slow infusion over 90 minutes every 14 days for a total of 6 injections

Intervention Type: DRUG

Placebo

NaCl 0.9% slow infusion over 90 minutes every 14 days for a total of 6 injections

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patient over 18 years of age
• With a symptomatic cerebral AVM (chronic headache, focal neurological deficit, cognitive impairment, epilepsy) of Spetzler and Martin grade III, IV or V.
• Whose symptoms are sufficiently severe to allow significant improvement with treatment:

• MoCA score ≤ 25 and/or
• NIHSS score ≥ 4 and/or
• Epilepsy Balance Score ≥ 2 and/or
• HIT-6 score ≥ 48
• With functional signs and symptoms not sequellar to a previous bleeding episode AND disabling (mRS>1)
• Ineligible for therapeutic intervention (endovascular or neurosurgery or radiosurgery)
• With normal bone marrow, liver and kidney function
• For women of childbearing potential: negative pregnancy test within 14 days of inclusion and effective contraception for up to 6 months after the end of treatment
• Having received informed consent to participate in the study
• Affiliated or beneficiary of a social security scheme

Exclusion Criteria

• Known allergy to bevacizumab or an excipient.
• Hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant human or humanized antibodies.
• Contraindication to cerebral MRI
• Absolute or relative contraindication to gadolinium injection
• Proteinuria ≥ 2+ on urine dipstick (patients with proteinuria ≥2+ on urine dipstick will need to have proteinuria ≤ 1g protein on 24-hour urine to be eligible)
• Uncontrolled hypertension (PAS >150 and/or PAD > 100 mmHg)
• History of hypertensive crisis or hypertensive encephalopathy
• Congestive heart failure (New York Heart Association Grade II or higher)
• Previous myocardial infarction or unstable angina in the preceding 12 months
• Symptomatic peripheral vascular disease
• Vascular disease (aortic aneurysm, aortic dissection)
• Major surgery, open biopsy or major traumatic lesion within 4 weeks prior to inclusion, or anticipation of the need for major surgery during the study.
• Biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to inclusion
• History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess in the 6 months prior to inclusion
• Significant unhealed wound, ulcer or bone fracture
• Thrombotic episode within 6 months prior to inclusion
• Atrial fibrillation
• Patient under legal protection
• Pregnant or breast-feeding women

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

HFAR

Paris, Île-de-France Region, France

Site Status: RECRUITING

Countries

France

Central Contacts

Jean-Philippe Désilles, MD, PhD

Role: CONTACT

jpdesilles@for.paris

01 48 03 64 54

Facility Contacts

Jean-Philippe Désilles, MD

Role: primary

jpdesilles@for.paris

+33148036913

Other Identifiers

JDS_2023_12

Identifier Type: -

Identifier Source: org_study_id